Akcea Therapeutics (AKCA) Form 3 AKCEA THERAPEUTICS / Kyle Jenne ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Jenne Kyle

(Last) (First) (Middle)

C/O AKCEA THERAPEUTICS, INC.

22 BOSTON WHARF ROAD, 9TH FLOOR

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/21/2019

3. Issuer Name and Ticker or Trading Symbol
AKCEA THERAPEUTICS, INC. [ AKCA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	11,711	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	06/04/2027	Common Stock	143,374	12.21	D
Stock Option (right to buy)	(1)	06/04/2027	Common Stock	32,751	12.21	D
Stock Option (right to buy)	(2)	01/01/2028	Common Stock	299	17.38	D
Stock Option (right to buy)	(2)	01/01/2028	Common Stock	13,701	17.38	D
Stock Option (right to buy)	(3)	01/01/2029	Common Stock	3,740	30.73	D
Stock Option (right to buy)	(3)	01/01/2029	Common Stock	27,510	30.73	D
Stock Option (right to buy)	(3)	01/01/2029	Common Stock	1,042	30.73	D
Stock Option (right to buy)	(3)	01/01/2029	Common Stock	48,958	30.73	D

Explanation of Responses:

1. The shares vest as follows: 1/4th of the shares vest one year after May 15, 2017;1/48th of the shares vest monthly thereafter over the next three years.

2. The shares vest as follows: 1/4th of the shares vest one year after January 2, 2018;1/48th of the shares vest monthly thereafter over the next three years.

3. The shares vest as follows: 1/4th of the shares vest one year after January 2, 2019;1/48th of the shares vest monthly thereafter over the next three years.

Remarks:

	/s/ Joshua F. Patterson, Attorney-in-Fact	10/23/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.